Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer

To evaluate the prevalence and prognostic role of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in patients with non-immunotherapy-treated advanced cervical cancer. Clinical data were retrospectively collected from medical records between January 1, 2008, and Decembe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of gynecologic oncology Ročník 35; číslo 6; s. e105 - 11
Hlavní autoři: Baek, Min-Hyun, Chen, Lei, Tekin, Cumhur, Cristescu, Razvan, Jin, Xiao Yang, Shao, Changxia, Ihm, Soo Yeon, Jelinic, Petar, Park, Jeong-Yeol
Médium: Journal Article
Jazyk:angličtina
Vydáno: Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 01.11.2024
대한부인종양학회
Témata:
Adenocarcinoma - genetics
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adult
Aged
B7-H1 Antigen - genetics
B7-H1 Antigen - metabolism
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Carcinoma, Adenosquamous - genetics
Carcinoma, Adenosquamous - mortality
Carcinoma, Adenosquamous - pathology
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Female
Humans
Middle Aged
Mutation
Neoplasm Recurrence, Local - epidemiology
Neoplasm Recurrence, Local - genetics
Original
Prevalence
Prognosis
Retrospective Studies
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - mortality
Uterine Cervical Neoplasms - pathology
산부인과학
Cervical Cancer
PD-L1 Protein
ISSN:2005-0380, 2005-0399, 2005-0399
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:To evaluate the prevalence and prognostic role of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in patients with non-immunotherapy-treated advanced cervical cancer. Clinical data were retrospectively collected from medical records between January 1, 2008, and December 31, 2016, at Asan Medical Center (Korea); archived tumor samples were assessed for PD-L1 expression (combined positive score [CPS] ≥1) and TMB (≥175 mutations/exome). Overall survival (OS) was defined as time from advanced diagnosis or initiation of first-line or second-line systemic therapy until death/last follow-up. The association of OS with PD-L1 expression and TMB were analyzed using the log-rank test and Cox proportional hazards model adjusted for covariates. Of 267 patients, 76.0% had squamous cell carcinoma (SCC), 24.0% had adenocarcinoma (AC)/adenosquamous carcinoma (ASC), 64.4% had PD-L1 CPS ≥1, and 32.6% had TMB ≥175 mutations/exome. PD-L1 CPS ≥1 and TMB ≥175 mutations/exome were more prevalent in SCC than in AC/ASC (73.9% and 37.2% vs. 34.4% and 17.7%). There was no association between OS and PD-L1 expression (CPS ≥1 vs. <1: adjusted hazard ratio [HR]=1.14; 95% confidence interval [CI]=0.84-1.53 from advanced diagnosis); OS trended shorter for the subgroup with TMB ≥175 versus <175 mutations/exome (adjusted HR=1.29; 95% CI=0.95-1.75). Retrospective analysis of non-immunotherapy-treated patients with advanced cervical cancer demonstrated a higher prevalence of PD-L1 CPS ≥1 and TMB ≥175 mutations/exome in SCC versus AC/ASC. PD-L1 CPS ≥1 was not associated with OS; TMB ≥175 mutations/exome showed a trend toward shorter OS. Additional studies are needed to confirm these findings.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current affiliation: Department of Obstetrics and Gynecology, School of Medicine, Kangwon National University, Chuncheon, Korea
https://doi.org/10.3802/jgo.2024.35.e105
ISSN:2005-0380
2005-0399
2005-0399
DOI:10.3802/jgo.2024.35.e105